Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance

Abstract To identify risk factors for the prognosis of prostate cancer (PC), we retrospectively analyzed the impact of lifestyle-related disorders as well as PC characteristics at initial diagnosis on the progression to castration-resistant PC (CRPC) in PC patients undergoing hormone therapy. Of 648...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tomonori Hayashi, Tomoyoshi Miyamoto, Noriaki Nagai, Atsufumi Kawabata
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9be7617cad6749498196df2c4e85778a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9be7617cad6749498196df2c4e85778a
record_format	dspace
spelling	oai:doaj.org-article:9be7617cad6749498196df2c4e85778a2021-12-02T16:34:54ZDevelopment of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance10.1038/s41598-021-96584-12045-2322https://doaj.org/article/9be7617cad6749498196df2c4e85778a2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96584-1https://doaj.org/toc/2045-2322Abstract To identify risk factors for the prognosis of prostate cancer (PC), we retrospectively analyzed the impact of lifestyle-related disorders as well as PC characteristics at initial diagnosis on the progression to castration-resistant PC (CRPC) in PC patients undergoing hormone therapy. Of 648 PC patients, 230 who underwent hormone therapy and met inclusion criteria were enrolled in this study. CRPC developed in 48 patients (20.9%). Univariate analysis using Cox proportional hazard model indicated that newly developed diabetes mellitus (DM) following hormone therapy (postDM), but not preexisting DM, as well as PC characteristics at initial diagnosis including prostate-specific antigen (PSA) ≥ 18 were significantly associated with the progression to CRPC. A similar tendency was also observed in the relationship between newly developed hypertension following hormone therapy and CRPC progression. On the other hand, neither dyslipidemia nor hyperuricemia, regardless the onset timing, exhibited any association with CRPC progression. In multivariate analysis, postDM and PSA ≥ 18 were extracted as independent risk factors for CRPC progression (adjusted hazard ratios, 3.38 and 2.34; p values, 0.016 and 0.019, respectively). Kaplan–Meier analysis and log-rank test clearly indicated earlier progression to CRPC in PC patients who developed postDM or had relatively advanced initial PC characteristics including PSA ≥ 18. Together, the development of lifestyle-related disorders, particularly DM, following hormone therapy, as well as advanced PC characteristics at initial diagnosis is considered to predict earlier progression to CRPC and poor prognosis in PC patients undergoing hormone therapy.Tomonori HayashiTomoyoshi MiyamotoNoriaki NagaiAtsufumi KawabataNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tomonori Hayashi Tomoyoshi Miyamoto Noriaki Nagai Atsufumi Kawabata Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
description	Abstract To identify risk factors for the prognosis of prostate cancer (PC), we retrospectively analyzed the impact of lifestyle-related disorders as well as PC characteristics at initial diagnosis on the progression to castration-resistant PC (CRPC) in PC patients undergoing hormone therapy. Of 648 PC patients, 230 who underwent hormone therapy and met inclusion criteria were enrolled in this study. CRPC developed in 48 patients (20.9%). Univariate analysis using Cox proportional hazard model indicated that newly developed diabetes mellitus (DM) following hormone therapy (postDM), but not preexisting DM, as well as PC characteristics at initial diagnosis including prostate-specific antigen (PSA) ≥ 18 were significantly associated with the progression to CRPC. A similar tendency was also observed in the relationship between newly developed hypertension following hormone therapy and CRPC progression. On the other hand, neither dyslipidemia nor hyperuricemia, regardless the onset timing, exhibited any association with CRPC progression. In multivariate analysis, postDM and PSA ≥ 18 were extracted as independent risk factors for CRPC progression (adjusted hazard ratios, 3.38 and 2.34; p values, 0.016 and 0.019, respectively). Kaplan–Meier analysis and log-rank test clearly indicated earlier progression to CRPC in PC patients who developed postDM or had relatively advanced initial PC characteristics including PSA ≥ 18. Together, the development of lifestyle-related disorders, particularly DM, following hormone therapy, as well as advanced PC characteristics at initial diagnosis is considered to predict earlier progression to CRPC and poor prognosis in PC patients undergoing hormone therapy.
format	article
author	Tomonori Hayashi Tomoyoshi Miyamoto Noriaki Nagai Atsufumi Kawabata
author_facet	Tomonori Hayashi Tomoyoshi Miyamoto Noriaki Nagai Atsufumi Kawabata
author_sort	Tomonori Hayashi
title	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
title_short	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
title_full	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
title_fullStr	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
title_full_unstemmed	Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
title_sort	development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9be7617cad6749498196df2c4e85778a
work_keys_str_mv	AT tomonorihayashi developmentofdiabetesmellitusfollowinghormonetherapyinprostatecancerpatientsisassociatedwithearlyprogressiontocastrationresistance AT tomoyoshimiyamoto developmentofdiabetesmellitusfollowinghormonetherapyinprostatecancerpatientsisassociatedwithearlyprogressiontocastrationresistance AT noriakinagai developmentofdiabetesmellitusfollowinghormonetherapyinprostatecancerpatientsisassociatedwithearlyprogressiontocastrationresistance AT atsufumikawabata developmentofdiabetesmellitusfollowinghormonetherapyinprostatecancerpatientsisassociatedwithearlyprogressiontocastrationresistance
_version_	1718383769793069056

Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance

Ejemplares similares